Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 27(5): 2077-2090, 2023 03.
Article in English | MEDLINE | ID: mdl-36930507

ABSTRACT

OBJECTIVE: The present study was taken up to evaluate the combination of two drugs in the management of behavioral disorders such as locomotor activity, muscle relaxation, analgesic, and anxiolytic activity. MATERIALS AND METHODS: In the methodology, Wistar rats weighing (150-180 g) were divided into six groups of 6 each (n=6). All the animals (groups II to VI) were subjected to stress and analyzed for anxiolytic activity using an elevated plus maze. The animals were treated for 28 days with poppy seed oil in lower and higher doses (1,000 and 2,000 mg/kg), tramadol in lower and higher doses (1.5 and 3 mg/kg) as individual groups, and one group with a combination of both drugs in lower doses. RESULTS: The results depicted showed that the combined treatment had significantly (**p <0.001) improvised behavior deficits, extemporized, and diminished anxiety-like attitude in rats, and showed the analgesic property in a significant manner. The pro-inflammatory cytokines TNF-α and IL-1ß were evaluated in the serum and were observed to be lessened the values of both in a significant manner with the co-administration of both the test drugs. The dopamine concentrations were also determined in the serum, which disclosed a decline (**p <0.001) significantly. CONCLUSIONS: It was concluded from the results that a combined effect of drugs might be beneficial in the management of behavioral disorders and pain management.


Subject(s)
Anti-Anxiety Agents , Papaver , Plant Oils , Tramadol , Animals , Rats , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Behavior, Animal , Cytokines , Dopamine , Motor Activity , Rats, Wistar , Tramadol/pharmacology , Plant Oils/pharmacology
2.
Biomed Pharmacother ; 117: 109123, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31234026

ABSTRACT

Chrysanthemum trifurcatum is common to Mediterranean countries and widely-used in traditional medicine. Due to the scarcity of data about the pharmacological properties of C. trifurcatum, this present study was designed to determine the effects of C. trifurcatumethanolic extract (CEE) for its anti-nociceptive, anti-epileptic, anti-inflammatory, and hepatoprotective activities in mice and rat models. We demonstrate that CEE contains alkaloids, carbohydrates, and flavonoids, and in a dose-dependent (300 and 500 mg/kg) manner exhibited significant reductions in paracetamol (PCM; 500 mg/kg)-induced increased serum AST, ALT and ALP levels, similar to as seen by silymarin (25 mg/kg). Additionally, CEE (300 mg/kg) elicited inhibition in acetic acid-induced abdominal writhes, delayed latency time to paw's licking in hot plate tests, exerted an anti-convulsant effect by prolonging the onset of clonic and tonic convulsions, and reduced pentylenetetrazole (PTZ; 80 mg/kg)-induced mortality. Moreover, CEE (500 mg/kg) exhibited a prominent reduction in carrageenan-induced paw edema. These studies indicate that CEE possesses profound central and peripheral analgesic, anti-convulsant, anti-inflammatory, and hepatoprotective activities.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Anticonvulsants/pharmacology , Asteraceae/chemistry , Liver/pathology , Protective Agents/pharmacology , Animals , Carrageenan , Female , Liver/drug effects , Mice , Nociception/drug effects , Phytochemicals/analysis , Rats, Wistar , Tramadol/pharmacology , Valproic Acid/pharmacology
3.
Paediatr Anaesth ; 28(10): 841-851, 2018 10.
Article in English | MEDLINE | ID: mdl-30117229

ABSTRACT

BACKGROUND: The impact of tramadol in children given acetaminophen-ibuprofen combination therapy is uncertain in acute pediatric pain management. A model describing the interaction between these three drugs would be useful to understand the role of supplemental analgesic therapy. METHODS: Children undergoing tonsillectomy were given oral paracetamol and ibuprofen perioperatively. Blood was taken for paracetamol and ibuprofen drug assay on up to six occasions over 6 h after the initial dose. Tramadol was administered by caregivers for unacceptable postoperative pain. Pain was measured using the Parent's Postoperative Pain Measurement rating two hourly on the first postoperative day. A first-order absorption, one-compartment linear model with first-order elimination was used to describe acetaminophen and ibuprofen disposition. Analgesia was described using an EMAX model extended for three drugs, assuming additive effects. Curve fitting was performed using nonlinear mixed effects models. RESULTS: Pharmacodynamic parameter estimates, expressed using fractional Hill equation, were maximum effect (EMAX ) 0.65 (95%CI 0.54, 0.74), the concentration of acetaminophen associated with 50% of the maximal drug effect (C50,ACET ) 7.06 (95%CI 7.03, 7.72) mg/L, and the ibuprofen C50 (C50,IBU ) 3.95 (95%CI 2.57, 7.53) mg/L. The Hill coefficient was 1.48 (95%CI 0.92, 2.62) and an interaction term was fixed at zero (additivity). The half-time (t1/2 keo) for equilibration between the plasma and effect site was 0.34 hour (95%CI 0.23, 1.98) for acetaminophen and 1.04 hour (95%CI 0.75, 1.77) for ibuprofen. Tramadol had a C50,TRAM of 0.07 (95%CI 0.048, 1.07) mg/L with a t1/2 keo,TRAM 1.78 hour (95%CI 1.06, 1.96). CONCLUSION: Ibuprofen has an EC50 for analgesia in children similar to that of adults (3.95 mg/L; 95%CI 2.57-7.53, vs 5-10 mg/L adults). The maximum effect from combination therapy (ie, 65% reduction in pain score) achieves satisfactory analgesia with commonly used doses but increased dose adds little additional benefit. The addition of tramadol to this analgesic mixture prolongs analgesia duration.


Subject(s)
Acetaminophen/pharmacokinetics , Analgesics, Non-Narcotic/pharmacokinetics , Ibuprofen/pharmacokinetics , Pain, Postoperative/drug therapy , Tramadol/pharmacokinetics , Acetaminophen/blood , Acetaminophen/pharmacology , Adenoidectomy/methods , Administration, Oral , Child , Child, Preschool , Drug Interactions , Drug Therapy, Combination , Humans , Ibuprofen/blood , Ibuprofen/pharmacology , Models, Biological , Pain Management/methods , Pain, Postoperative/blood , Pain, Postoperative/metabolism , Tonsillectomy/methods , Tramadol/blood , Tramadol/pharmacology
4.
Braz J Med Biol Res ; 51(4): e7124, 2018 Mar 01.
Article in English | MEDLINE | ID: mdl-29513798

ABSTRACT

Marasmius androsaceus is a medicinal fungus mainly used to treat various forms of pain in China. This study investigated the analgesic effects of an ethanol extract of M. androsaceus (MAE) and its potential molecular mechanisms. Oral administration of MAE (50, 200, and 1000 mg/kg) had significant analgesic effects in an acid-induced writhing test, a formalin test, and a hot-plate test, with effectiveness similar to tramadol (the positive control drug). The autonomic activity test showed that MAE had no harmful effects on the central nervous system in mice. MAE resulted in significantly enhanced levels of noradrenalin and 5-hydroxytryptamine in serum but suppressed both of these neurotransmitters in the hypothalamus after 30 s of hot-plate stimulation. Co-administration with nimodipine (10 mg/kg; a Ca2+ channel blocker) strongly enhanced the analgesic effect in the hot-plate test compared to MAE alone. Moreover, MAE down-regulated the expression of calmodulin-dependent protein kinase II (CaMKII) in the hypothalamus after a 30-s thermal stimulus. These results suggested that the analgesic ability of MAE is related to the regulation of metabolism by monoamine neurotransmitters and Ca2+/CaMKII-mediated signaling, which can potentially aid the development of peripheral neuropathic pain treatments obtained from M. androsaceus.


Subject(s)
Analgesics/pharmacology , Marasmius/chemistry , Pain/drug therapy , Plant Extracts/pharmacology , Tramadol/pharmacology , Animals , Disease Models, Animal , Male , Mice , Pain Measurement/drug effects
5.
Metab Brain Dis ; 33(3): 907-916, 2018 06.
Article in English | MEDLINE | ID: mdl-29470767

ABSTRACT

Tramadol, a frequently used pain reliever drug, present neurotoxic effects associated to cognitive dysfunction. Moreover, crocin has been reported to have neuroprotective effects. The aim of this study was to assess crocin's capacity to protect learning, and memory abilities on tramadol-treated rats. A total of 35 rats were divided into five groups: Control, Saline, tramadol (50 mg/kg), tramadol + crocin(30 mg/kg), crocin groups and treated orally for 28 consecutive days. Morris water maze (MWM) and passive avoidance (PA) tests were done, followed by dissection of the rat's brains for toluidine blue and TUNEL staining. In MWM test, tramadol group spent lower time and traveled shorter distance in the target quadrant (Q1) (P < 0.05). On the other side, the traveled distance in tramadol-crocin group was higher than tramadol (P < 0.05). In PA test, both the delay for entering the dark, and the total time spent in the light compartment decreased in tramadol comparing to the control group (P < 0.05), while it increased in tramadol-crocin compared with the tramadol group (P < 0.05). In tramadol-treated animals, the dark neurons (DNs) and apoptotic cells in CA1, CA3 and DG increased (P < 0.05), while concurrent intake of crocin decreased the number of DNs and apoptotic cells in these areas (P < 0.05). Crocin was able to improve learning and memory of tramadol-treated rats and also decreased DNs and apoptotic cells in the hippocampus. Considering these results, the potential capacity of crocin for decreasing side effects of tramadol on the nervous system is suggested.


Subject(s)
Apoptosis/drug effects , Carotenoids/pharmacology , Hippocampus/drug effects , Memory/drug effects , Tramadol/pharmacology , Animals , Antioxidants/pharmacology , Male , Maze Learning/drug effects , Memory Disorders/drug therapy , Neurons/drug effects , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Rats, Wistar
6.
Pain Manag Nurs ; 19(1): 46-53, 2018 02.
Article in English | MEDLINE | ID: mdl-29248605

ABSTRACT

Black older adults often experience disparities in pain treatment that results in unmet pain needs. The aims of this study were to assess the pain management experiences of a group of community dwelling Black older adults and identify gaps in clinical practice. A qualitative, descriptive design was employed using the methodology of ethnography. The setting was an urban, low-income, community elderly housing high-rise facility. Participants included facility residents (n = 106); of these, 20 completed structured qualitative interviews. The Brief Pain Inventory and qualitative interviews were used to determine pain prevalence, treatment practices, and barriers. Eighty-six percent of the participants had severe pain with a mean worst pain rating of 7 on a 0 to 10 scale. Pain interfered moderately with general activity (5.59), walking (5.73) and normal work (5.70), also measured on 0 to 10 scales. Participants preferred non-opioid analgesics, topical over-the-counter treatments, and nonpharmacological interventions such as prayer/meditation, and exercise for treatment. Medications most commonly used by participants for pain management included, hydrocodone with acetaminophen (28.6%), nonsteroidal anti-inflammatory drugs (13.2%), acetaminophen with codeine (12%), and tramadol (9.9). Qualitative interviews revealed that pain management barriers were centered around communication concerns about side effects, fears of addiction, and provider mistrust. A communication gap exists between patients and providers. Discussing patient treatment preferences, providing balanced treatment information, and following-up with patients on treatment plan effectiveness by phone can improve how pain is managed for Black older adults.


Subject(s)
Black or African American/statistics & numerical data , Pain Management/standards , Pain/drug therapy , Black or African American/ethnology , Aged , Anthropology, Cultural/methods , Codeine/pharmacology , Codeine/therapeutic use , Exercise Therapy/methods , Faith Healing/psychology , Faith Healing/standards , Female , Healthcare Disparities/ethnology , Healthcare Disparities/statistics & numerical data , Housing for the Elderly/organization & administration , Housing for the Elderly/statistics & numerical data , Humans , Hydrocodone/pharmacology , Hydrocodone/therapeutic use , Ibuprofen/pharmacology , Ibuprofen/therapeutic use , Male , Medicine, Traditional/methods , Middle Aged , Naproxen/pharmacology , Naproxen/therapeutic use , Pain Management/methods , Pain Measurement/methods , Psychometrics/instrumentation , Psychometrics/methods , Psychometrics/statistics & numerical data , Qualitative Research , Surveys and Questionnaires , Tramadol/pharmacology , Tramadol/therapeutic use
7.
Braz. j. med. biol. res ; 51(4): e7124, 2018. graf
Article in English | LILACS | ID: biblio-889061

ABSTRACT

Marasmius androsaceus is a medicinal fungus mainly used to treat various forms of pain in China. This study investigated the analgesic effects of an ethanol extract of M. androsaceus (MAE) and its potential molecular mechanisms. Oral administration of MAE (50, 200, and 1000 mg/kg) had significant analgesic effects in an acid-induced writhing test, a formalin test, and a hot-plate test, with effectiveness similar to tramadol (the positive control drug). The autonomic activity test showed that MAE had no harmful effects on the central nervous system in mice. MAE resulted in significantly enhanced levels of noradrenalin and 5-hydroxytryptamine in serum but suppressed both of these neurotransmitters in the hypothalamus after 30 s of hot-plate stimulation. Co-administration with nimodipine (10 mg/kg; a Ca2+ channel blocker) strongly enhanced the analgesic effect in the hot-plate test compared to MAE alone. Moreover, MAE down-regulated the expression of calmodulin-dependent protein kinase II (CaMKII) in the hypothalamus after a 30-s thermal stimulus. These results suggested that the analgesic ability of MAE is related to the regulation of metabolism by monoamine neurotransmitters and Ca2+/CaMKII-mediated signaling, which can potentially aid the development of peripheral neuropathic pain treatments obtained from M. androsaceus.


Subject(s)
Animals , Male , Mice , Pain/drug therapy , Tramadol/pharmacology , Plant Extracts/pharmacology , Marasmius/chemistry , Analgesics/pharmacology , Pain Measurement/drug effects , Disease Models, Animal
8.
Neuropharmacology ; 125: 231-242, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28760650

ABSTRACT

Grip strength deficit is a measure of pain-induced functional disability in rheumatic disease. We tested whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show parallels in their response to analgesics and basic mechanisms. Mice with periarticular injections of complete Freund's adjuvant (CFA) in the ankles showed periarticular immune infiltration and synovial membrane alterations, together with pronounced grip strength deficits and tactile allodynia measured with von Frey hairs. However, inflammation-induced tactile allodynia lasted longer than grip strength alterations, and therefore did not drive the functional deficits. Oral administration of the opioid drugs oxycodone (1-8 mg/kg) and tramadol (10-80 mg/kg) induced a better recovery of grip strength than acetaminophen (40-320 mg/kg) or the nonsteroidal antiinflammatory drugs ibuprofen (10-80 mg/kg) or celecoxib (40-160 mg/kg); these results are consistent with their analgesic efficacy in humans. Functional impairment was generally a more sensitive indicator of drug-induced analgesia than tactile allodynia, as drug doses that attenuated grip strength deficits showed little or no effect on von Frey thresholds. Finally, ruthenium red (a nonselective TRP antagonist) or the in vivo ablation of TRPV1-expressing neurons with resiniferatoxin abolished tactile allodynia without altering grip strength deficits, indicating that the neurobiology of tactile allodynia and grip strength deficits differ. In conclusion, grip strength deficits are due to a distinct type of pain that reflects an important aspect of the human pain experience, and therefore merits further exploration in preclinical studies to improve the translation of new analgesics from bench to bedside.


Subject(s)
Arthritis/diagnosis , Hand Strength , Hyperalgesia/diagnosis , Muscle Strength , Pain Measurement , Rheumatic Diseases/diagnosis , Acetaminophen/pharmacology , Analgesics/pharmacology , Animals , Arthritis/drug therapy , Arthritis/pathology , Arthritis/physiopathology , Celecoxib/pharmacology , Disease Models, Animal , Diterpenes/pharmacology , Female , Freund's Adjuvant , Hyperalgesia/drug therapy , Hyperalgesia/pathology , Hyperalgesia/physiopathology , Ibuprofen/pharmacology , Inflammation/diagnosis , Inflammation/drug therapy , Inflammation/pathology , Inflammation/physiopathology , Muscle Strength/drug effects , Nociceptors/drug effects , Nociceptors/metabolism , Nociceptors/pathology , Oxycodone/pharmacology , Pain Measurement/methods , Rheumatic Diseases/drug therapy , Rheumatic Diseases/pathology , Rheumatic Diseases/physiopathology , Ruthenium Red/pharmacology , TRPV Cation Channels/antagonists & inhibitors , TRPV Cation Channels/metabolism , Tarsus, Animal , Touch , Tramadol/pharmacology
9.
Brain Res Bull ; 134: 136-141, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28754288

ABSTRACT

Tramadol is an analgesic agent that is mainly used to treat moderate to severe pain. There is evidence that tramadol may have antidepressant property. However, the mechanisms underlying the antidepressant effects of tramadol have not been elucidated yet. Considering that fact that N-methyl-d-aspartate (NMDA) receptor signaling may play an important role in the pathophysiology of depression, the aim of the present study was to investigate the role of NMDA receptor signaling in the possible antidepressant-like effects of tramadol in the mouse forced swimming test (mFST). We found that tramadol exerted antidepressant-like effects at high dose (40mg/kg, intraperitoneally [i.p.]) in the mFST. Co-administration of non-effective doses of NMDA receptor antagonists (ketamine [1mg/kg, i.p.], MK-801 [0.05mg/kg, i.p.], or magnesium sulfate [10mg/kg, i.p.]) with sub-effective dose of tramadol (20mg/kg, i.p.) exerted significant antidepressant-like effects in the mFST. The antidepressant-like effects of tramadol (40mg/kg) was also inhibited by pre-treatment with non-effective dose of the NMDA receptor agonist NMDA (75mg/kg, i.p.). Our data suggest a role for NMDA receptor signaling in the antidepressant-like effects of tramadol in the mFST.


Subject(s)
Antidepressive Agents/pharmacology , Depressive Disorder/drug therapy , Receptors, N-Methyl-D-Aspartate/metabolism , Tramadol/pharmacology , Animals , Depressive Disorder/metabolism , Disease Models, Animal , Dizocilpine Maleate/pharmacology , Dose-Response Relationship, Drug , Excitatory Amino Acid Agents/pharmacology , Ketamine/pharmacology , Magnesium Sulfate/pharmacology , Male , Mice , N-Methylaspartate/pharmacology , Receptors, N-Methyl-D-Aspartate/agonists , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Swimming
10.
Nat Rev Dis Primers ; 3: 17002, 2017 Feb 16.
Article in English | MEDLINE | ID: mdl-28205574

ABSTRACT

Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aß, Aδ and C fibres) and central neurons, and affects 7-10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and inhibitory somatosensory signalling, alterations in ion channels and variability in the way that pain messages are modulated in the central nervous system all have been implicated in neuropathic pain. The burden of chronic neuropathic pain seems to be related to the complexity of neuropathic symptoms, poor outcomes and difficult treatment decisions. Importantly, quality of life is impaired in patients with neuropathic pain owing to increased drug prescriptions and visits to health care providers, as well as the morbidity from the pain itself and the inciting disease. Despite challenges, progress in the understanding of the pathophysiology of neuropathic pain is spurring the development of new diagnostic procedures and personalized interventions, which emphasize the need for a multidisciplinary approach to the management of neuropathic pain.


Subject(s)
Neuralgia/complications , Neuralgia/diagnosis , Pain Management/methods , Quality of Life/psychology , Amines/pharmacology , Amines/therapeutic use , Analgesics/pharmacology , Analgesics/therapeutic use , Cyclohexanecarboxylic Acids/pharmacology , Cyclohexanecarboxylic Acids/therapeutic use , Drug Therapy, Combination/methods , Gabapentin , Humans , Lidocaine/pharmacology , Lidocaine/therapeutic use , Narcotics/pharmacology , Narcotics/therapeutic use , Neoplasms/complications , Neuralgia/epidemiology , Nociceptive Pain/complications , Nociceptive Pain/diagnosis , Pregabalin/pharmacology , Pregabalin/therapeutic use , Tramadol/pharmacology , Tramadol/therapeutic use , Transcutaneous Electric Nerve Stimulation/methods , Transcutaneous Electric Nerve Stimulation/standards , Voltage-Gated Sodium Channel Blockers/pharmacology , Voltage-Gated Sodium Channel Blockers/therapeutic use , gamma-Aminobutyric Acid/pharmacology , gamma-Aminobutyric Acid/therapeutic use
11.
Neurourol Urodyn ; 36(7): 1742-1748, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27935110

ABSTRACT

AIMS: To determine the role of opioid receptors in the inhibition of bladder overactivity by sacral neuromodulation (SNM) in pigs, and explore the possible mechanism of SNM. METHODS: Both implant-driven stimulators of the S3 spinal nerve were implanted in seven pigs. Naloxone and tramadol were administered. Multiple cystometrograms were performed to determine the effects of SNM and opioid receptors on the micturition reflex by infusing normal saline (NS) or acetic acid (AA). RESULTS: AA-induced bladder overactivity significantly reduced the bladder capacity (BC) to 29.9 ± 3.9% of the NS control level (413.1 ± 55.4 mL) (P < 0.01). SNM significantly increased the BC to 39.4 ± 5.5% of the NS control level (P < 0.03). In the absence of SNM, the cumulative dose of naloxone (0.02 and 0.2 mg/kg intravenously) did not significantly change the BC (25.1 ± 3.1% and 20.2 ± 3.1% of the NS control level, respectively) (P > 0.05). In the presence of SNM, both doses of naloxone significantly reduced the BC to 27.2 ± 3.0% and 25.1 ± 2.9% of the NS control level (P < 0.05), respectively. In the absence of SNM, tramadol did not significantly change the BC (31.5 ± 3.9% of the NS control level) (P > 0.05). In the presence of SNM, tramadol significantly increased the BC to 49.1 ± 6.1% of the NS control level (P < 0.01). CONCLUSIONS: Opioid receptors play a role in inhibition of bladder overactivity during SNM. Combining SNM with tramadol could be a novel treatment modality for overactive bladder.


Subject(s)
Naloxone/pharmacology , Spinal Nerves/drug effects , Tramadol/pharmacology , Transcutaneous Electric Nerve Stimulation , Urinary Bladder, Overactive/therapy , Urination/physiology , Acetic Acid , Animals , Female , Male , Naloxone/therapeutic use , Reflex/drug effects , Sacrum , Swine , Urinary Bladder, Overactive/chemically induced , Urinary Bladder, Overactive/physiopathology , Urination/drug effects
12.
Genet Mol Res ; 15(3)2016 Aug 30.
Article in English | MEDLINE | ID: mdl-27706666

ABSTRACT

Paecilomyces hepiali (PH), a well-known medicinal fungus, has various pharmacological efficacies. In our study, the antinociceptive effects of PH and underlying mechanisms were evaluated using various mouse models. An acetic acid-induced writhing test, hot plate test, and formalin test were employed to evaluate the antinociceptive activities of PH. The levels of neuronal nitric oxide synthase (nNOS) in the hypothalamus and monoamine neurotransmitters in the serum and hypothalamus of experimental mice were examined. Additionally, hot plate tests using mice pretreated with various antagonists were used to determine the mechanisms of PH-mediated antinociception. The PH-enhanced latency period of mice in the hot plate test was significantly blocked by pretreatment with atropine and glibenclamide. PH shortened the phase I and phase II reaction times of formalin-treated mice. Strongly reduced writhing and stretching induced by acetic acid were observed in PH-treated mice, indicating that PH mainly exerts antinociceptive activity on neurogenic pain. After thermal pain stimulation for 30 s, compared to control mice, 7-day PH-treated mice had lower nNOS and dopamine levels, and increased levels of serotonin in both the serum and hypothalamus. Collectively, our data showed that PH mediated antinociceptive activities via multiple pathways, including monoamines, nNOS/ATP-sensitive K+ channels, and M-type acetylcholine receptors.


Subject(s)
Analgesics/pharmacology , Paecilomyces/chemistry , Animals , Drug Evaluation, Preclinical , Female , Hypothalamus/drug effects , Hypothalamus/enzymology , Mice, Inbred BALB C , Mycelium/chemistry , Nitric Oxide Synthase Type I/metabolism , Tramadol/pharmacology
13.
Nat Prod Rep ; 33(9): 1034-43, 2016 Sep 25.
Article in English | MEDLINE | ID: mdl-27346294

ABSTRACT

Covering up to 2016Nauclea latifolia (syn. Sarcocephalus latifolius, Rubiaceae), commonly called the African pincushion tree, is a plant widely used in folk medicine in different regions of Africa for treating a variety of illnesses, including malaria, epilepsy and pain. N. latifolia has not only drawn the interest of traditional healers but also of phytochemists, who have identified a range of bioactive indole alkaloids in its tissue. More recently, following up on the traditional use of extracts in pain management, a bio-guided purification from the roots of the tree led to the identification of the active ingredient as tramadol, available as a synthetic analgesic since the 1970s. The discovery of this compound as a natural phytochemical was highlighted worldwide. This review focuses on the correlation between extracted compounds and pharmacological activities, paying special attention to infectious diseases and neurologically-related disorders. A critical analysis of the data reported so far on the natural origin of tramadol and its proposed biosynthesis is also presented.


Subject(s)
Indole Alkaloids , Rubiaceae/chemistry , Tramadol/pharmacology , Trees/chemistry , Analgesics, Opioid/therapeutic use , Animals , Indole Alkaloids/chemistry , Indole Alkaloids/isolation & purification , Indole Alkaloids/pharmacology , Malaria/drug therapy , Medicine, Traditional , Molecular Structure , Plant Roots/chemistry , Tramadol/chemistry , Tramadol/isolation & purification , Tramadol/metabolism
14.
Am J Ther ; 23(6): e1554-e1559, 2016.
Article in English | MEDLINE | ID: mdl-26934730

ABSTRACT

This study is designed to evaluate the analgesic and anti-inflammatory activities of aqueous extract (AE) of Cistus ladanifer L. leaves in experimental animal models. The central analgesic activity of C. ladanifer AE is studied using hot plate method in rats, and the acute anti-Inflammatory activity of C. ladanifer is investigated by rats paw edema induced by subplantar injection of 0.5% carrageenan into the right hind paw. Rats are pretreated with AE of C. ladanifer at different doses (150, 175, and 200 mg/kg, i.p.). The tramadol and indomethacin are used as reference drugs for analgesic and anti-inflammatory studies, respectively. Our results show that the AE of C. ladanifer exhibited anti-inflammatory and analgesic effects dose dependent. In anti-inflammatory activity, the AE of C. ladanifer at all doses reduced significantly the edema paw inflammation after carrageenan injection. Furthermore at 200 mg/kg, the effect of AE is highly important than that of other doses. In addition, the same AE demonstrates significant analgesic effect in thermal-induced pain model. So, this activity is proved by significant reduction of pain score after administration of AE at all doses. The nociception protection effects in this case are, respectively, 70.3%, 74.55%, and 93.33% after administration of AE of C. ladanifer at doses 150, 175, and 200 mg/kg b.w. The results of our findings suggest that AE of C. ladanifer has potential analgesic and anti-inflammatory activities with evidence of possible involvement of peripheral and central effects in its actions.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Cistus/chemistry , Plant Extracts/pharmacology , Analgesics/administration & dosage , Analgesics/isolation & purification , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/isolation & purification , Carrageenan , Disease Models, Animal , Dose-Response Relationship, Drug , Edema/drug therapy , Indomethacin/pharmacology , Inflammation/drug therapy , Inflammation/pathology , Male , Morocco , Pain/drug therapy , Pain/pathology , Plant Extracts/administration & dosage , Rats , Rats, Wistar , Tramadol/pharmacology
15.
Am J Ther ; 23(6): e1695-e1699, 2016.
Article in English | MEDLINE | ID: mdl-26872137

ABSTRACT

This study aims to investigate the antidepressant and analgesic properties of the aqueous extract of Anethum graveolens L. from South of Morocco (Rissani-Errachidia region). Extract of plant is obtained by aqueous decoction and administered to Wistar rats orally. The extract has a significant antidepressant and analgesic effects compared with the drug references (sertraline and tramadol) without any adverse effects. The dose of 250 mg/kg, body weight shows the best antidepressant and analgesic effects than 1 g/kg, body weight. Phytochemical study of the aqueous extract of the plant has to show its highlight in polyphenols, flavonoids, and tannins.


Subject(s)
Analgesics/pharmacology , Anethum graveolens , Antidepressive Agents/pharmacology , Plant Extracts/chemistry , Plant Extracts/pharmacology , Analgesics/chemistry , Animals , Antidepressive Agents/chemistry , Dose-Response Relationship, Drug , Flavonoids , Male , Morocco , Polyphenols , Rats , Rats, Wistar , Sertraline/pharmacology , Tannins , Tramadol/pharmacology
16.
Artif Cells Nanomed Biotechnol ; 44(8): 1793-1802, 2016 Dec.
Article in English | MEDLINE | ID: mdl-26584819

ABSTRACT

CONTEXT: Tramadol is a centrally acting analgesic and requires frequent dosing. Hence, judicious selection of retarding formulations is necessary. Transdermal ethosomal gel delivery has been recognized as an alternative route to oral delivery. OBJECTIVE: The objective was to develop statistically optimized ethosomal systems for enhanced transdermal activity of tramadol vis-à-vis traditional liposomes. MATERIALS AND METHODS: Box-Behnken design was employed for optimization of nanoethosomes using phospholipon 90G (A), ethanol (B), and sonication time (C) as independent variables while dependent variables were the vesicle size (Y1), entrapment efficiency (Y2), and flux (Y3). It was prepared by rotary evaporation method and characterized for various parameters including entrapment efficiency, size and transflux. Preclinical assessments were conducted on Wistar rats to measure the performance of developed formulations. RESULTS: The optimized formulation provided mean vesicles size, reasonable entrapment efficiency and enhanced flux when compared with liposome (control). In-vivo absorption study showed a significant increase in bioavailability (7.51 times) compared with oral tramadol. The average primary irritancy index was found to be 1.4, indicating it to be non-irritant and safe for use. DISCUSSION AND CONCLUSION: The results also demonstrated that encapsulated tramadol increases its biological activity due to the superior skin penetration potential. The preclinical study indicates a significant (P < 0.05) extended analgesic effect compared to oral solution using the hot plate test method. The overall results suggest that developed formulation is an efficient carrier for transdermal delivery of tramadol.


Subject(s)
Analgesics, Opioid , Tramadol , Administration, Topical , Analgesics, Opioid/chemistry , Analgesics, Opioid/pharmacokinetics , Analgesics, Opioid/pharmacology , Animals , Drug Evaluation, Preclinical , Liposomes , Rats , Rats, Wistar , Skin Absorption , Tramadol/chemistry , Tramadol/pharmacokinetics , Tramadol/pharmacology
17.
Behav Brain Res ; 301: 142-51, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26704218

ABSTRACT

BACKGROUND: It has recently been suggested that non-reflex behavioral readouts, such as burrowing, may be used to evaluate the efficacy of analgesics in rodent models of pain. OBJECTIVE: To confirm whether intraplantar Complete Freund's Adjuvant (CFA)-induced pain reliably results in burrowing deficits which can be ameliorated by clinically efficacious analgesics as previously suggested. METHODS: Uni- or bilateral intraplantar CFA injections were performed in male Wistar Han rats. The time- and concentration-response of burrowing deficits and the ability of various analgesics to reinstate burrowing performance were studied. An anxiolytic was also tested to evaluate the motivational cue that drives this behavior. RESULTS: Burrowing deficits were dependent on the concentration of CFA injected, most pronounced 24h after CFA injections and even more pronounced after bilateral compared with unilateral injections. Celecoxib and ibuprofen reversed CFA-induced burrowing deficits whereas indomethacin failed to significantly reinstate burrowing performance. Morphine and tramadol failed to reinstate burrowing performance, but sedation was observed in control rats at doses thought to be efficacious. An antibody directed against the nerve growth factor significantly improved CFA-induced burrowing deficits. Neither gabapentin nor the anxiolytic diazepam reinstated burrowing performance and the opportunity to find shelter did not modify burrowing performance. CONCLUSION: Burrowing is an innate behavior reliably exhibited by rats. It is suppressed in a model of inflammatory pain and differently reinstated by clinically efficacious analgesics that lack motor impairing side effects, but not an anxiolytic, suggesting that this assay is suitable for the assessment of analgesic efficacy of novel drugs.


Subject(s)
Analgesics/pharmacology , Behavior, Animal/drug effects , Inflammation/physiopathology , Motor Activity/drug effects , Pain/diagnosis , Pain/drug therapy , Amines/pharmacology , Animals , Antibodies/pharmacology , Celecoxib/pharmacology , Cyclohexanecarboxylic Acids/pharmacology , Diazepam/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Freund's Adjuvant , Gabapentin , Ibuprofen/pharmacology , Indomethacin/pharmacology , Inflammation/drug therapy , Male , Morphine/pharmacology , Nerve Growth Factor/immunology , Pain/physiopathology , Rats, Wistar , Tramadol/pharmacology , gamma-Aminobutyric Acid/pharmacology
18.
Eur J Pain ; 20(2): 274-83, 2016 Feb.
Article in English | MEDLINE | ID: mdl-25919941

ABSTRACT

BACKGROUND: Rutin is a bioflavonoid found in fruits, vegetables and plants used in traditional medicine to alleviate pain. However, rutin's scientific evidence for the modulation of pain and its mechanism of action is lacking. It is well known that the periaqueductal grey matter (PAG) contains opioidergic neural circuits involved in the modulation of descending nociception. The aim of this study was to investigate if antinociceptive activity of rutin is modulated by the PAG circuitry involving participation of opioid receptors. METHODS: The experimental design included groups of rats receiving rutin systemically (30-1000 mg/kg) or microinjected into the vlPAG (8-32 nmol/4 µL) alone or in the presence of an opioid antagonist, naltrexone (5 mg/kg, i.p. or 26 nmol/4 µL, respectively). Nociception was assessed using the formalin test and compared versus the reference drugs, tramadol and morphine. RESULTS: Systemic or intra-vlPAG administration of rutin significantly decreased both phases of the formalin test. Antinociceptive responses of the reference drugs were prevented by naltrexone, whereas the antinociceptive effect of rutin was inhibited by this antagonist mainly in the phase II of the formalin test. CONCLUSIONS: Our results provide evidence that rutin produces antinociceptive effects involving central modulation of the vlPAG descending circuit partly mediated by an opioidergic mechanism.


Subject(s)
Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Nociception/drug effects , Pain/drug therapy , Periaqueductal Gray/drug effects , Rutin/therapeutic use , Animals , Male , Microinjections , Morphine/pharmacology , Morphine/therapeutic use , Narcotics/pharmacology , Narcotics/therapeutic use , Pain Measurement , Rats , Rats, Wistar , Receptors, Opioid/agonists , Rutin/pharmacology , Tramadol/pharmacology , Tramadol/therapeutic use
19.
J Pharmacol Sci ; 129(3): 196-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26598003

ABSTRACT

In the present study, we investigated the effect of a Kampo medicine Goshajinkigan (GJG) on the bortezomib-induced mechanical allodynia in von Frey test in rats. The single administration of tramadol (10 mg/kg), GJG (1.0 g/kg) and its component processed Aconiti tuber (0.1 g/kg) significantly reversed the reduction in withdrawal threshold by bortezomib. These effects were abolished by the intrathecal injection of nor-binaltorphimine (10 µg/body), kappa opioid receptor antagonist. These findings suggest that kappa opioid receptor is involved in the effect of GJG on the bortezomib-induced mechanical allodynia.


Subject(s)
Bortezomib/adverse effects , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/pharmacology , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Phytotherapy , Receptors, Opioid, kappa/physiology , Aconitum , Animals , Male , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Rats, Sprague-Dawley , Receptors, Opioid, kappa/antagonists & inhibitors , Tramadol/administration & dosage , Tramadol/pharmacology
20.
Adv Clin Exp Med ; 24(3): 419-27, 2015.
Article in English | MEDLINE | ID: mdl-26467129

ABSTRACT

BACKGROUND: Whereas some studies have demonstrated the essential role of 5-hydroxytryptamine (5-HT) in tramadol and acetaminophen analgesia, other research has presented conflicting results. To dispel doubts, some aspects of the involvement of 5-HT in the antinociceptive properties of these drugs remain to be clarified. OBJECTIVES: The aim of this study was to determine whether the serotoninergic system dysfunction produced by neonatal 5-HT lesion in rats may affect the antinociceptive effects of tramadol and acetaminophen administered in adulthood. MATERIAL AND METHODS: Three days after birth, the control rats were pretreated with desipramine HCl (20 mg/kg i.p.) 30 min before intraventricular saline--vehicle injection. A separate group received 5.7-DHT; 2×35 µg in each lateral ventricle. At the age of 8 weeks, 5-HT and 5-hydroxyidoleaceticacid (5-HIAA) concentrations were determined in the thalamus and spinal cord by an HPLC/ED method. The antinociceptive effects of tramadol (20 mg/kg i.p.) or acetaminophen (100 mg/kg i.p.) were evaluated by a battery of tests. RESULTS: 5.7-DHT lesioning was associated with a reduction in 5-HT and 5-HIAA content of the thalamus (>85% and >90%) and spinal cord (>58% and 70%). Neonatal 5.7-DHT treatment produced a significant reduction in the antinociceptive effect of tramadol in the hot plate, tail-immersion, paw withdrawal and writhing tests. In the formalin hind paw test, the results were ambiguous. 5-HT lesion was also associated with a decrease in the analgesic effect of acetaminophen in the hot plate and writhing tests. A similar relationship wasn't found in the other assessments conducted with the use of acetaminophen. CONCLUSIONS: The present study provides evidence that (1) an intact serotoninergic system is required for the adequate antinociceptive action of tramadol, and (2) the serotoninergic system exerts a negligible influence on acetaminophen-induced analgesia in rats. We hypothesize that similar abnormalities in nociception may occur in patients with 5-HT dysfunction (e.g. depression), so these results should be complied in analgesic dosage adjustment.


Subject(s)
5,7-Dihydroxytryptamine/toxicity , Acetaminophen/pharmacology , Analgesics, Non-Narcotic/pharmacology , Analgesics, Opioid/pharmacology , Pain Perception/drug effects , Pain/prevention & control , Spinal Cord/drug effects , Thalamus/drug effects , Tramadol/pharmacology , Age Factors , Animals , Animals, Newborn , Disease Models, Animal , Hydroxyindoleacetic Acid/metabolism , Male , Pain/etiology , Pain/metabolism , Pain/physiopathology , Pain/psychology , Pain Measurement , Rats, Wistar , Serotonergic Neurons/drug effects , Serotonergic Neurons/metabolism , Serotonin/metabolism , Spinal Cord/metabolism , Spinal Cord/physiopathology , Thalamus/metabolism , Thalamus/physiopathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL